White Paper

Enhancing mRNA Vaccine Production Efficiency With Single Use Technologies

Source: Chargepoint Technology

By Ben Wylie

mRNA GettyImages-1356994723

In the future, as mRNA technology usage expands, drug manufacturers will have to utilize new approaches to optimize manufacturing efficiency. The speed at which COVID-19 vaccines were developed and produced on a vast scale made the need for efficiency even more prominent, along with an expectation to continue matching that production speed. This aspiration to maximize efficiency should be balanced with the need to ensure compliance to the new Annex 1 guidelines ahead of their implementation. Explore how to pursue the desire for enhanced production efficiency whilst increasing sterility assurance and using single-use technology.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online